UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 54

Sortiert nach

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

The New England journal of medicine, 2023-06, Vol.388 (22), p.2058-2070

2023

Volltextzugriff (PDF)

Association of anthracyclines induced cardiotoxicity (AIC) in patients with early breast cancer (eBC) with germline BRCA1/2 (gBRCA1/2) mutation: BRCAN study

Journal of clinical oncology, 2023-06, Vol.41 (16_suppl), p.567-567

2023

Volltextzugriff (PDF)

992 Impact of molecular status on chemotherapy response score (CRS) in advanced epithelial ovarian cancer (AEOC)

International journal of gynecological cancer, 2024-03, Vol.34 (Suppl 1), p.A387-A388

2024

Volltextzugriff (PDF)

Rectal adenocarcinoma: Outcomes of adjuvant chemotherapy after neoajuvant chemoradiotherapy in a retrospective cohort

Journal of clinical oncology, 2017-02, Vol.35 (4_suppl), p.790-790

2017

Volltextzugriff (PDF)

Tumor markers as predictors of outcome in patients with advanced esophagogastric adenocarcinoma (EGA) treated with chemotherapy

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e15061-e15061

2015

Volltextzugriff (PDF)

Outcome of metastases resection from gastric cancer: A Spanish multicenter retrospective study

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e15069-e15069

2015

Volltextzugriff (PDF)

Rectal adenocarcinoma: Results of adjuvant chemotherapy in a retrospective cohort

Journal of clinical oncology, 2015-05, Vol.33 (15_suppl), p.e14539-e14539

2015

Volltextzugriff (PDF)

Abstract P3-09-03: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study)

Cancer research (Chicago, Ill.), 2020-02, Vol.80 (4_Supplement), p.P3-P3-09-03

2020

Volltextzugriff (PDF)

Abstract CT152: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study)

Cancer research (Chicago, Ill.), 2018-07, Vol.78 (13_Supplement), p.CT152-CT152

2018

Volltextzugriff (PDF)

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

Neuro-oncology (Charlottesville, Va.), 2023-01, Vol.25 (1), p.157-166

2023

Volltextzugriff (PDF)

I-SPY2 platform: New lessons from the olaparib and durvalumab combination in breast cancer treatment

Cancer cell, 2021-07, Vol.39 (7), p.902-904

2021

Volltextzugriff (PDF)

Top advances of the year: Breast cancer

Cancer, 2023-06, Vol.129 (12), p.1791-1794

2023

Volltextzugriff (PDF)

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain

International journal of molecular sciences, 2023-07, Vol.24 (15), p.12031

2023

Volltextzugriff (PDF)

Oligometastatic Disease: When Stage IV Breast Cancer Could Be “Cured”

Cancers, 2022-10, Vol.14 (21), p.5229

2022

Volltextzugriff (PDF)

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

The Lancet (British edition), 2020-12, Vol.396 (10265), p.1817-1828

2020

Volltextzugriff (PDF)

Can we cure oligometastatic disease? A practical point of view

Current opinion in oncology, 2020-11, Vol.32 (6), p.568

2020

Volltextzugriff (PDF)

Atezolizumab in the treatment of metastatic triple-negative breast cancer

Expert opinion on biological therapy, 2020-09, Vol.20 (9), p.981-989

2020

Volltextzugriff (PDF)

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature

Frontiers in oncology, 2023-05, Vol.13, p.1158981

2023

Volltextzugriff (PDF)

Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects

Therapeutic Advances in Medical Oncology, 2021-11, Vol.13, p.17588359211059587

2021

Volltextzugriff (PDF)

Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study

International journal of infectious diseases, 2022-10, Vol.123, p.97-103

2022

Volltextzugriff (PDF)

1 – 25 von 54

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(50)
Mit Volltextzugriff
(50)

Publikationsform

Artikel
(53)
Berichte
(1)

Sprache

Englisch
(54)

Erscheinungsjahr

n.n

Thema

Life Sciences & Biomedicine
(26)
Science & Technology
(26)
Breast Cancer
(19)
Oncology
(17)
Humans
(14)
Female
(12)
Patients
(10)
Breast Neoplasms - Drug Therapy
(9)
Cancer Therapies
(9)
Chemotherapy
(9)
Tumors
(8)
Immunotherapy
(7)
Metastasis
(7)
Survival
(7)
Antibodies, Monoclonal, Humanized - Therapeutic Use
(6)
Erbb-2 Protein
(6)
Metastases
(6)
Trastuzumab - Therapeutic Use
(6)
Adverse Events
(5)
Lymphocytes
(5)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Capivasertib in Hormone Receptor–Positive Advanced Breast Cancer

Association of anthracyclines induced cardiotoxicity (AIC) in patients with early breast cancer (eBC) with germline BRCA1/2 (gBRCA1/2) mutation: BRCAN study

992 Impact of molecular status on chemotherapy response score (CRS) in advanced epithelial ovarian cancer (AEOC)

Prognostic biomarkers after colorectal liver metastasis resection: Exploratory study for VEGF, VEGFR and SPARC expression

Rectal adenocarcinoma: Surveillance and timing of surgical resection after neoadjuvant chemoradiotherapy in a retrospective cohort

Rectal adenocarcinoma: Outcomes of adjuvant chemotherapy after neoajuvant chemoradiotherapy in a retrospective cohort

Outcomes of elderly patients receiving neoadjuvant chemoradiation and adjuvant chemotherapy for locally advanced rectal cancer in a retrospective cohort

Tumor markers as predictors of outcome in patients with advanced esophagogastric adenocarcinoma (EGA) treated with chemotherapy

Outcome of metastases resection from gastric cancer: A Spanish multicenter retrospective study

Rectal adenocarcinoma: Results of adjuvant chemotherapy in a retrospective cohort

Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC)

Abstract P3-09-03: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study)

Abstract CT152: A phase II study of pembrolizumab and eribulin in patients with HR-positive/HER2-negative metastatic breast cancer previously treated with anthracyclines and taxanes (KELLY study)

Trastuzumab deruxtecan in patients with central nervous system involvement from HER2-positive breast cancer: The DEBBRAH trial

I-SPY2 platform: New lessons from the olaparib and durvalumab combination in breast cancer treatment

Top advances of the year: Breast cancer

Binding Affinity of Trastuzumab and Pertuzumab Monoclonal Antibodies to Extracellular HER2 Domain

Oligometastatic Disease: When Stage IV Breast Cancer Could Be “Cured”

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial

Can we cure oligometastatic disease? A practical point of view

Atezolizumab in the treatment of metastatic triple-negative breast cancer

Limited T cell response to SARS-CoV-2 mRNA vaccine among patients with cancer receiving different cancer treatments

Maintained complete response to talazoparib in a BRCA-2 mutated metastatic luminal breast cancer: case report and review of literature

Surrogate endpoints for early-stage breast cancer: a review of the state of the art, controversies, and future prospects

Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study

Suchergebnisse filtern